Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 4
2006 8
2007 5
2008 5
2009 4
2010 2
2011 5
2012 5
2013 5
2014 3
2015 4
2016 9
2017 13
2018 13
2019 14
2020 12
2021 33
2022 35
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.
Trépo E, Caruso S, Yang J, Imbeaud S, Couchy G, Bayard Q, Letouzé E, Ganne-Carrié N, Moreno C, Oussalah A, Féray C, Blanc JF, Clément B, Hillon P, Boursier J, Paradis V, Calderaro J, Gnemmi V, Nault JC, Guéant JL, Devière J, Archambeaud I, Vitellius C, Turlin B, Bronowicki JP, Gustot T, Sutton A; GENTHEP Consortium; Ziol M, Nahon P, Zucman-Rossi J. Trépo E, et al. Among authors: ganne carrie n. Lancet Oncol. 2022 Jan;23(1):161-171. doi: 10.1016/S1470-2045(21)00603-3. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902334 Free article.
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D'Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. Bureau C, et al. Among authors: ganne carrie n. Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524293 Clinical Trial.
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC. Limousin W, et al. Among authors: ganne carrie n. J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28. J Hepatol. 2023. PMID: 37647991
Optimizing curative management of hepatocellular carcinoma.
Nahon P, Vibert E, Nault JC, Ganne-Carrié N, Ziol M, Seror O. Nahon P, et al. Among authors: ganne carrie n. Liver Int. 2020 Feb;40 Suppl 1:109-115. doi: 10.1111/liv.14345. Liver Int. 2020. PMID: 32077602 Review.
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
Elkrief L, Ganne-Carrié N, Manceau H, Tanguy M, Valainathan SR, Riescher-Tuczkiewicz A, Biquard L, Barget N, Chaffaut C, Louvet A, Paradis V, Ziol M, Bæk R, Jørgensen MM, Van Niel G, Coly PM, Hammoutène A, Dujardin F, Peoc'h K, Poynard T, Chevret S, Rautou PE; CIRRAL group. Elkrief L, et al. Among authors: ganne carrie n. J Hepatol. 2023 Oct;79(4):910-923. doi: 10.1016/j.jhep.2023.05.025. Epub 2023 Jun 9. J Hepatol. 2023. PMID: 37302582
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
Non-invasive diagnosis and follow-up of autoimmune hepatitis.
Lemoinne S, Heurgue A, Bouzbib C, Hanslik B, Gournay J, Nguyen-Khac E, Bureau C, de Lédinghen V, Ganne-Carrié N, Bourlière M. Lemoinne S, et al. Among authors: ganne carrie n. Clin Res Hepatol Gastroenterol. 2022 Jan;46(1):101772. doi: 10.1016/j.clinre.2021.101772. Epub 2021 Jul 28. Clin Res Hepatol Gastroenterol. 2022. PMID: 34332126 Review.
164 results